MRRS adds "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 – a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) – a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 – is a recent market entrant, gaining approval for treating advanced or metastatic squamous NSCLC patients in Japan in 2015 and in Australia in 2016. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.

Table of Contents
3 Marketed Products 30
3.1 Overview 30
3.2 Chemotherapies 30
3.2.1 Alimta (pemetrexed) - Eli Lilly 30
3.2.2 Abraxane (paclitaxel) - Celgene 31
3.3 Tarceva (erlotinib) - Roche 32
3.4 Iressa (gefitinib) - AstraZeneca 33
3.5 Gilotrif (afatinib) - Boehringer Ingelheim 34
3.6 Xalkori (crizotinib) - Pfizer 35
3.7 Avastin (bevacizumab) - Roche 36
3.8 Opdivo (nivolumab) - Bristol-Myers Squibb 37
3.9 Alecensa (alectinib) - Roche 38
3.10 Conclusion 39
3.11 Comparative Efficacy and Safety of Marketed Products 40
4 Pipeline Analysis 44
4.1 Overview 44
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 45
4.3 Pipeline by Molecular Target 46
4.4 Promising Pipeline Candidates 49
4.4.1 Ipilimumab - Bristol-Myers Squibb 49
4.4.2 Custirsen - OncoGenex 51
4.4.3 Atezolizumab - Roche 52
4.4.4 Necitumumab - Eli Lilly 54
4.4.5 Rociletinib - Clovis 55
4.4.6 Vaxira - Recombio 57
4.4.7 Keytruda - Merck 58
4.4.8 TG4010 - Transgene 60
4.4.9 Veliparib - AbbVie 61
4.4.10 Abemaciclib - Eli Lilly 63
4.4.11 Bavituximab - Peregrine Pharmaceuticals 64
4.4.12 Cyramza (Ramucirumab) - Eli Lilly 65
4.4.13 Zykadia (ceritinib/LDK378) - Novartis 67
4.4.14 Tagrisso (osimertinib/AZD-9291) - AstraZeneca 68
4.4.15 Dacomitinib - Pfizer 70
4.4.16 Selumetinib - AstraZeneca 71
4.5 Comparative Efficacy and Safety of Pipeline Products 72
4.6 Product Competitiveness Framework 73
5 Clinical Trial Analysis 75......

List of Tables and Figures 
Table 1: NSCLC Therapeutics Market, Tumor Node Metastasis Classification 22
Table 2: NSCLC Therapeutics Market, Eastern Co-operative Oncology Group Criteria 23
Table 3: NSCLC Therapeutics Market, Treatment Options 24
Table 4: NSCLC Therapeutics Market, Global, All Pipeline Products, Discovery, 2015 113
Table 5: NSCLC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2015 114
Table 6: NSCLC Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2015 118
Table 7: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase I, 2015 119
Table 8: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase II, 2015 123
Table 9: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase III, 2015 128
Table 10: NSCLC Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2015 130
Table 11: NSCLC Therapeutics Market, APAC, Market Forecast, 2015-2022 130.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/non-small-cell-lung-cancer-therapeutics-in-asia-pacific-markets-to-2022-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/